Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL12 | P48061 | 10/20 | 1.00 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.76 |
| ▸ | RELA | Q04206 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | KRAS | P01116 | 1/20 | 0.71 |
| ▸ | ATM | Q13315 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.70 |
| ▸ | TUBB | P07437 | 1/20 | 0.70 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.70 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.70 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.70 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.70 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.70 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.70 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.70 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.70 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.70 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25201290 | 1.00 | CXCL12 (1.00) | CXCL12CXCR4RELAALDH1A1KRAS | |
| SCHEMBL2246091 | 1.00 | CXCL12 (1.00) | CXCL12CXCR4RELAALDH1A1KRAS | |
| SCHEMBL30384286 | 1.00 | CXCL12 (1.00) | CXCL12CXCR4RELAALDH1A1KRAS | |
| SCHEMBL30383469 | 1.00 | CXCL12 (1.00) | CXCL12CXCR4RELAALDH1A1KRAS | |
| Water SCHEMBL25195597 | 0.99 | CXCL12 (0.97) | CXCL12CXCR4RELAALDH1A1KRAS | |
| SCHEMBL30384490 | 0.93 | CXCL12 (0.89) | CXCL12CXCR4RELATUBB4ATUBB | |
| SCHEMBL25193952 | 0.93 | CXCL12 (0.89) | CXCL12CXCR4RELATUBB4ATUBB | |
| SCHEMBL12677857 | 0.93 | CXCL12 (0.89) | CXCL12CXCR4RELATUBB4ATUBB | |
| SCHEMBL25199011 | 0.89 | CXCL12 (0.81) | CXCL12RELAALDH1A1KRASATM | |
| SCHEMBL25198994 | 0.89 | CXCL12 (0.81) | CXCL12RELAALDH1A1KRASATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| US-11046657-B2 | Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-06-29 | — | — | US | disclosed |
| US-20200181093-A1 | Pyrimidinone Derivatives and Uses Thereof to Neutralize the Biological Activity of Chemokines | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 2020-06-11 | — | — | US | disclosed |
| WO-2018011376-A1 | PYRIMIDINONE DERIVATIVES AND USES THEREOF TO NEUTRALIZE THE BIOLOGICAL ACTIVITY OF CHEMOKINES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - (FR) | 2018-01-18 | — | — | WO | disclosed |
| EP-2260039-B1 | CHALCONE LINKED PYRROLO[2,1-C[[1, 4]BENZODIAZEPINE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2013-12-04 | — | — | EP | disclosed |
| US-8461150-B2 | Chalcone linked pyrrolo[2,1-c][1, 4]benzodiazepine hybrids as potential anticancer agents and process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-06-11 | — | — | US | disclosed |
| US-20110201600-A1 | CHALCONE LINKED PYRROLO[2,1-C][1, 4]BENZODIAZEPINE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETIES ACT (ACT XXI OF 1860)) (IN) | 2011-08-18 | — | — | US | disclosed |
| EP-2260039-A1 | CHALCONE LINKED PYRROLO[2,1-C[[1, 4]BENZODIAZEPINE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | Council Of Scientific & Industrial Research (IN) | 2010-12-15 | — | — | EP | disclosed |
| WO-2009109986-A1 | CHALCONE LINKED PYRROLO[2,1-C][1, 4]BENZODIAZEPINE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201600-A1 | CHALCONE LINKED PYRROLO[2,1-C][1, 4]BENZODIAZEPINE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | CYP2E1, CYP4B1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CXCL12 1349/4885CXCR4 372/4885RELA 2287/4885 |
| US-20200181093-A1 | Pyrimidinone Derivatives and Uses Thereof to Neutralize the Biological Activity of Chemokines | CCL5, CXCR3, CXCL10 | CXCL12 18/4885CXCR4 12/4885RELA 237/4885 |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | CXCL12 399/4885CXCR4 1201/4885RELA 1254/4885 |
| US-11046657-B2 | Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines | CCL5, CXCR3, CXCL10 | CXCL12 18/4885CXCR4 12/4885RELA 237/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | CXCL12 287/4885CXCR4 1725/4885RELA 1879/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | CXCL12 287/4885CXCR4 1725/4885RELA 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.